Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Bone. 2021 Apr 30;150:115993. doi: 10.1016/j.bone.2021.115993

Figure 3: Mineral deposition of MC3T3 cells treated with increasing concentrations of the Ezh2 inhibitors CPI-169, GSK503 and CPI-1205.

Figure 3:

Alizarin red staining of triplicate MC3T3 cell cultures at day 26 of osteogenic differentiation after treatment in the first week with vehicle (DMSO; 1:2,000 dilution), or a 1X or a 2X dose of increasing concentrations of CPI-169, GSK503 and CPI-1205.